Susan O’Brien

4.6k citations

69 papers · 3.1k indexed · h-index 29

Hematology top 0.2%
Genetics top 0.5%
Molecular Biology top 10%
Public Health, Environmental and Occupational Health top 2%
Oncology top 5%

Co-authors: Hagop M. Kantarjian Jörge E. Cortes Farhad Ravandi Guillermo Garcia‐Manero Moshe Talpaz Stefan Faderl Elias Jabbour Emil J. Freireich
Topics: Chronic Lymphocytic Leukemia Research (29 papers)Acute Myeloid Leukemia Research (29 papers)Chronic Myeloid Leukemia Treatments (26 papers)
Cited by: Hematology Genetics Rheumatology
Journals: New England Journal of Medicine Journal of Clinical Oncology Blood
Partner nations: United States Germany United Kingdom

In The Last Decade

Susan O’Brien

67 papers receiving 3.1k citations

Peers

Countries citing papers authored by Susan O’Brien

Since Specialization

Citations

This map shows the geographic impact of Susan O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan O’Brien more than expected).

Fields of papers citing papers by Susan O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan O’Brien. The network helps show where Susan O’Brien may publish in the future.

Co-authorship network of co-authors of Susan O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Susan O’Brien. A scholar is included among the top collaborators of Susan O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan O’Brien. Susan O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial 2019 ·Leukemia Research ·(unknown),Nicola Gökbuget,Anjali S. Advani,Matthias Stelljes,Wendy Stock,Michaela Liedtke,Giovanni Martinelli,Susan O’Brien,Tao Wang,Alexander Laird,Erik Vandendries,(unknown),Kevin T. Nguyen,Naveen Dakappagari,Daniel J. DeAngelo,Hagop Kantarjian	37
2	Chronic Lymphocytic Leukemia: Diagnosis and Treatment 2018 ·Mayo Clinic Proceedings ·Paolo Strati,Nitin Jain,Susan O’Brien	25
3	Monoclonal antibodies in acute lymphoblastic leukemia 2015 ·Blood ·Elias Jabbour,Susan O’Brien,Farhad Ravandi,Hagop M. Kantarjian	111
4	Retrospective Analysis of Prognostic Factors Associated With Response and Overall Survival by Baseline Marrow Blast Percentage in Patients With Myelodysplastic Syndromes Treated With Decitabine 2013 ·Clinical Lymphoma Myeloma & Leukemia ·Elias Jabbour,Hagop M. Kantarjian,Susan O’Brien,Tapan M. Kadia,(unknown),(unknown),(unknown),Jörge E. Cortes,Farhad Ravandi,Guillermo Garcia‐Manero	5
5	Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome 2013 ·Clinical Lymphoma Myeloma & Leukemia ·Hady Ghanem,A. Megan Cornelison,Guillermo Garcia‐Manero,Hagop M. Kantarjian,Farhad Ravandi,Tapan M. Kadia,Jörge E. Cortes,Susan O’Brien,Mark Brandt,Gautam Borthakur,Elias Jabbour	2
6	Survival Outcomes In Relapsed/Refractory Acute Myeloid Leukemia Patients Who Achieve Less-Than-Complete Response After Salvage Therapy 2013 ·Blood ·(unknown),Hagop M. Kantarjian,Farhad Ravandi,Susan O’Brien,Guillermo Garcia‐Manero,Michael Andreeff,Marina Konopleva,Elias Jabbour,Sherry R. Pierce,Gautam Borthakur,Jörge E. Cortes	2
7	A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome 2010 ·Cancer ·Elias Jabbour,Hagop M. Kantarjian,Farhad Ravandi,Guillermo Garcia‐Manero,Zeev Estrov,Srđan Verstovšek,Susan O’Brien,Stefan Faderl,Deborah A. Thomas,James R. Wright,Jörge E. Cortes	32
8	Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities 2009 ·Cancer ·Farhad Ravandi,Jean‐Pierre J. Issa,Guillermo Garcia‐Manero,Susan O’Brien,Sherry Pierce,Jianqin Shan,Gautam Borthakur,Srđan Verstovšek,Stefan Faderl,Jörge E. Cortes,Hagop M. Kantarjian	68
9	Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia. 2009 ·Blood ·Sameer A. Parikh,Michael A. Keating,Susan O’Brien,Alessandra Ferrajoli,Stefan Faderl,Charles Koller,Zeev Estrov,Susan Lerner,William G. Wierda	10
10	Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2′-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia. 2005 ·Blood ·Guillermo Garcia‐Manero,Hagop M. Kantarjian,Blanca Sánchez‐González,Hui Yang,Gary L. Rosner,Srđan Verstovšek,Michael Rytting,Farhad Ravandi,Stefan Faderl,Zeev Estrov,Jörge E. Cortes,Susan O’Brien,Jackie Fiorentino,Jean‐Pierre J. Issa	3
11	Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes 2003 ·Leukemia ·Salim Yazji,Francis J. Giles,Apostolia M. Tsimberidou,Elihu H. Estey,Hagop M. Kantarjian,Susan O’Brien,Razelle Kurzrock	65
12	Phase I Study of Taxol in Refractory Acute Myelogenous Leukemias Using a Weekly Schedule 1998 ·Acta Haematologica ·Reinhold Munker,Hagop M. Kantarjian,Susan O’Brien,Michael J. Keating,Michael Andreeff,Elihu H. Estey	7
13	ECONOMIC COSTS OF EXPANDED CRITERIA DONORS IN RENAL TRANSPLANTATION1 1998 ·Transplantation ·James F. Whiting,(unknown),Roger Smith,Susan O’Brien,Matthew R. First,J. Wesley Alexander	28
14	Treatment of chronic myelogenous leukemia: current status and investigational options [see comments] 1996 ·Blood ·(unknown),Susan O’Brien,Paolo Anderlini,Moshe Talpaz	155
15	Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection 1995 ·Journal of Clinical Apheresis ·Jeane P. Hester,María Cecilia Dignani,Elias Anaissie,Hagop M. Kantarjian,Susan O’Brien,Emil J. Freireich	67
16	Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimen 1994 ·British Journal of Haematology ·Hagop M. Kantarjian,Susan O’Brien,Terry Smith,Elihu H. Estey,(unknown),A. Preti,Sherry Pierce,Michael J. Keating	46
17	Preliminary Results of Treatment with Filgrastim for Relapse of Leukemia and Myelodysplasia after Allogeneic Bone Marrow Transplantation 1993 ·New England Journal of Medicine ·Sergio Giralt,(unknown),Hagop M. Kantarjian,Albert Deisseroth,Emil J. Freireich,Börje S. Andersson,Susan O’Brien,Michael Andreeff,Harold Fisher,Ann Cork,Cheryl Hirsch‐Ginsberg,José M. Trujillo,Sanford A. Stass,Richard E. Champlin	77
18	Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia 1991 ·Cancer ·(unknown),Moshe Talpaz,Michael J. Keating,Elihu H. Estey,Susan O’Brien,Miloslav Beran,K. B. McCredie,J. U. Gutterman,Emil J. Freireich	34
19	An analysis of the effects of seed weight, seed rate and date of harvest on the yield and economic value of seed-potato crops 1987 ·The Journal of Agricultural Science ·E. J. Allen,Susan O’Brien	6
20	Comparisons of growth and early yields of potato varieties of contrasting maturity classification at three sites 1984 ·The Journal of Agricultural Science ·Reginald Griffith,E. J. Allen,Susan O’Brien,P. J. O’Brien	7

About Susan O’Brien

Susan O’Brien is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health, having authored 69 papers that have together received 3.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (29 papers), Acute Myeloid Leukemia Research (29 papers) and Chronic Myeloid Leukemia Treatments (26 papers). The work is most often cited by research in Hematology (2.2k citations), Genetics (1.3k citations) and Rheumatology (441 citations). Susan O’Brien has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Farhad Ravandi, Guillermo Garcia‐Manero, Moshe Talpaz, Stefan Faderl, Elias Jabbour, Emil J. Freireich, Srđan Verstovšek and Francis J. Giles. Their work appears in journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact